Changes at the FDA have altered the device approval landscape, with the de novo route now the most popular.
Some medtech stocks did decline in 2018, but many more increased in value.
Forming partnerships with a number of players in diabetes technology is the key to growth, according to Ascensia Diabetes Care.
Dexcom can capitalise on its new algorithm technology, but is now enmeshed in a tangled web of partnerships.
The Danish company’s latest deal covers glucose-sensitive insulin, which could avoid hypoglycaemia in type 2 diabetes patients.
Regulatory intervention having limited impact on fostering innovation.
Smaller medtechs saw impressive share price growth in 2018, but not quite as good as the year before.
Battle of the algorithms.
Can a device control a patient’s blood sugar based on bodyweight alone?